Document headings vary by document type but may contain
                    the following: the agency or agencies that issued and signed a document
the number of the CFR title and the number of each part
                      the document amends, proposes to amend, or is directly
                      related to
the agency docket number / agency internal file number
the RIN which identifies each regulatory action listed in
                      the Unified Agenda of Federal Regulatory and Deregulatory
                      Actions See the
                    Document Drafting Handbook
                    for more details.
 Department of Health and Human Services Food and Drug Administration 21 CFR Parts 510 and 558
 AGENCY: Food and Drug Administration, HHS.
 ACTION: Final rule.
 SUMMARY: The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect the change of sponsor for three approved new animal drug applications (NADAs) for oxytetracycline premixes from Pfizer, Inc., to Phibro Animal Health, Inc.  The drug labeler code for Phibro Animal Health, Inc., is also being listed.
 DATES: This rule is effective June 18, 2001.
 FOR FURTHER INFORMATION CONTACT: Norman J. Turner, Center for Veterinary Medicine (HFV-102), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301-827-0214.


SUPPLEMENTARY INFORMATION: Pfizer, Inc., 235 East 42d St., New York, NY 10017-5755, has informed FDA that it has transferred ownership of, and all rights and interests in, NADA 8-804 for Terramycin® (oxytetracycline) Type A medicated articles, NADA 38-439 for Terramycin® (oxytetracycline) for fish, and NADA 95-143 for OXTC® (oxytetracycline) Type A medicated articles to Phibro Animal Health, Inc., One Parker Plaza, Fort Lee, NJ 07024.  Accordingly, the agency is amending the regulations in 21 CFR 558.450 to reflect the transfer of ownership. In addition, Phibro Animal Health, Inc., has not been previously listed in the animal drug regulations as a sponsor of an approved application.  At this time, 21 CFR 510.600(c)(1) and (c)(2) is being amended to add entries for the firm. This rule does not meet the definition of “rule” in 5 U.S.C. 804(3)(A) because it is a rule of “particular applicability.” Therefore, it is not subject to the congressional review requirements in 5 U.S.C. 801-808. List of Subjects 21 CFR Part 510 Administrative practice and procedure
Animal drugs
Labeling
Reporting and recordkeeping requirements 21 CFR Part 558 Animal drugs
Animal feeds
 Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, 21 CFR parts 510 and 558 are amended as follows: PART 510—NEW ANIMAL DRUGS
 1.  The authority citation for 21 CFR part 510 continues to read as follows: Authority:
                    21 U.S.C. 321, 331, 351, 352, 353, 360b, 371, 379e. 2.  Section 510.600 is amended in the table in paragraph (c)(1) by alphabetically adding an entry for “Phibro Animal Health, Inc.” and in the table in paragraph (c)(2) by numerically adding an entry for “066104” to read as follows: § 510.600
 
 (c)  * * * (1)  * * * Firm name and address
Drug labeler code*         *         *         *         *         *         *Phibro Animal Health, Inc., One Parker Plaza, Fort Lee, NJ 07024
066104( print page 32740)*         *         *         *         *         *         *
 (2)  * * * Drug labeler code
Firm name and address*         *         *         *         *         *         *066104
Phibro Animal Health, Inc., One Parker Plaza, Fort Lee, NJ 07024*         *         *         *         *         *         *
 PART 558—NEW ANIMAL DRUGS FOR USE IN ANIMAL FEEDS
 3.  The authority citation for 21 CFR part 558 continues to read as follows: Authority:
                    21 U.S.C. 360b, 371. § 558.450
 4.  Section 558.450 
                    *Oxytetracycline*
                     is amended in paragraph (a)(1) by removing “000069” and by adding in its place “066104”; and in table 1 in paragraphs (d)(1)(i), (d)(1)(v), (d)(1)(vii), and (d)(1)(viii), under the “Sponsor” column, and in table 2 in paragraphs (d)(2)(i) through (d)(2)(iii), under the “Sponsor” column, by removing “000069” and by adding in its place “066104”. Dated: June 8, 2001. Claire M. Lathers, Director, Office of New Animal Drug Evaluation, Center for Veterinary Medicine.


[FR Doc. 01-15273 Filed 6-15-01; 8:45 am] BILLING CODE 4160-01-S